Citadel Advisors’s Satsuma Pharmaceuticals, Inc. Common Stock STSA Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q2 | – | Sell |
-5,397
| Closed | -$3.77K | – | 15665 |
|
|
2023
Q1 | $3.77K | Sell |
5,397
-4,515
| -46% | -$4.15K | ﹤0.01% | 14009 |
|
|
2022
Q4 | $8.92K | Buy |
+9,912
| New | +$28.7K | ﹤0.01% | 13720 |
|
|
2022
Q3 | – | Sell |
-150,954
| Closed | -$856K | – | 14014 |
|
|
2022
Q2 | $624K | Sell |
150,954
-34,656
| -19% | -$122K | ﹤0.01% | 8155 |
|
|
2022
Q1 | $706K | Sell |
185,610
-890,010
| -83% | -$4.01M | ﹤0.01% | 8556 |
|
|
2021
Q4 | $4.84M | Buy |
1,075,620
+3,006
| +0.3% | +$15.3K | ﹤0.01% | 4345 |
|
|
2021
Q3 | $5M | Sell |
1,072,614
-154,218
| -13% | -$817K | ﹤0.01% | 4296 |
|
|
2021
Q2 | $8.63M | Sell |
1,226,832
-10,666
| -0.9% | -$57.5K | ﹤0.01% | 3332 |
|
|
2021
Q1 | $7.31M | Buy |
1,237,498
+872,713
| +239% | +$5.29M | ﹤0.01% | 3493 |
|
|
2020
Q4 | $1.68M | Sell |
364,785
-22,528
| -6% | -$97.1K | ﹤0.01% | 5734 |
|
|
2020
Q3 | $1.51M | Sell |
387,313
-640,807
| -62% | -$12.9M | ﹤0.01% | 5260 |
|
|
2020
Q2 | $29.6M | Buy |
1,028,120
+7,703
| +0.8% | +$178K | 0.01% | 1184 |
|
|
2020
Q1 | $22M | Buy |
1,020,417
+2,935
| +0.3% | +$66.6K | 0.01% | 1168 |
|
|
2019
Q4 | $20M | Buy |
1,017,482
+59,100
| +6% | +$840K | 0.01% | 1479 |
|
|
2019
Q3 | $14.4M | Buy |
+958,382
| New | +$14.9M | 0.01% | 1812 |
|
Citadel Advisors's STSA Position: Q2 2023 in Review
Citadel Advisors sold out of Satsuma Pharmaceuticals, Inc. Common Stock (STSA) in Q2 2023, closing a stake of 5,397 shares — an estimated $3.77K sold.
Citadel Advisors first reported a position in STSA in Q3 2019 and held it in 14 quarters. The position peaked at $29.6M in Q2 2020. 0 funds tracked by Wall St. Rank hold STSA as of Q2 2023.
- Citadel Advisors reported no remaining Satsuma Pharmaceuticals, Inc. Common Stock position as of Q2 2023 after selling out during the quarter.
- Citadel Advisors sold 5,397 Satsuma Pharmaceuticals, Inc. Common Stock shares in Q2 2023, an estimated $3.77K.
- Citadel Advisors first reported a position in Satsuma Pharmaceuticals, Inc. Common Stock in Q3 2019 and held it in 14 quarters.
- Citadel Advisors's Satsuma Pharmaceuticals, Inc. Common Stock position peaked at $29.6M in Q2 2020.
- 0 funds tracked by Wall St. Rank held Satsuma Pharmaceuticals, Inc. Common Stock as of Q2 2023.
Based on Citadel Advisors's 13F filing for Q2 2023, filed 14 Aug 2023.